Lotus Pharmaceutical Co., Ltd. (TPE:1795)

Market Cap	70.74B +0.2%
Revenue (ttm)	18.66B +6.0%
Net Income	4.73B +9.2%
EPS	18.04 +9.5%
Shares Out	262.98M
PE Ratio	14.91
Forward PE	10.20
Dividend	5.78 (2.27%)
Ex-Dividend Date	Aug 11, 2025

Volume	40,000
Average Volume	5,695,909
Open	261.00
Previous Close	255.00
Day's Range	260.50 - 269.50
52-Week Range	172.50 - 369.50
Beta	0.28
RSI	35.59
Earnings Date	Mar 5, 2026

About Lotus Pharmaceutical

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1966
• Employees: 1,099
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1795

Financial Performance

In 2024, Lotus Pharmaceutical's revenue was 18.58 billion, an increase of 9.59% compared to the previous year's 16.96 billion. Earnings were 5.07 billion, an increase of 23.38%.